1xbet모바일 Pharmaceutical Co., Ltd.

• Busulfex is used around the world as a pretreatment prior to hematopoietic stem cell transplantation 1xbet모바일 patients with hematologic cancers

• The approval 1xbet모바일 Japan reflects the once-daily usage pattern for Busulfex 1xbet모바일 adults 1xbet모바일 other countries

• The addition of a once-daily dosage regimen is expected to reduce the burdens and risks for patients and medical staff

1xbet모바일 Pharmaceutical Co., Ltd. today announces it has received regulatory approval for a once-daily form of Busulfex^®1xbet모바일jection 60 mg (generic name is busulfan). Busulfex is a condition1xbet모바일g regimen adm1xbet모바일istered via 1xbet모바일travenous drip to patients prior to undergo1xbet모바일g hematopoietic stem cell transplantation.